ArticleCancers2022

Neither Tumor-Infiltrating Lymphocytes nor Cytotoxic T Cells Predict Enhanced Benefit from Chemotherapy in the DBCG77B Phase III Clinical Trial.

Elahe Shenasa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.